Prediction of CYP-mediated drug interactions in vivo using in vitro data
Related Experiment Video
Updated: Jun 27, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Robert S Foti1, Jan L Wahlstrom
1Amgen Inc, 1201 Amgen Court W, Seattle, WA 98119, USA.
Abstract:
Over the past 15 years, a concerted effort has been undertaken by the pharmaceutical industry to reduce the attrition of clinical candidates resulting from undesirable ADME characteristics. Increasing regulatory and competitive pressures demand that pharmaceutical products brought to the market possess pristine safety and drug co-administration profiles for most therapeutic areas. The high-profile withdrawal of drugs such as mibefradil from the market because of unfavorable drug-drug interaction profiles has focused efforts on screening for cytochrome P450 (CYP)-mediated drug interactions early in the discovery paradigm and on predicting the impact of inhibition on the in vivo situation. This paper discusses current practices used to screen for CYP-mediated drug-drug interactions in vitro (inhibition and induction) and how these data are being used to predict whether a clinically relevant drug-drug interaction is likely to occur in vivo.
More Related Videos
Related Concept Videos
Drug Product Performance: In Vitro–In Vivo Correlation
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacokinetics: Drug–Drug Interactions
Pharmacogenetics of Drug Metabolism: Overview
Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
Drug toxicity: Drug–Drug Interaction

